Crosstalk of the heart and periphery: Skeletal and cardiac muscle as therapeutic targets in heart failure

被引:2
|
作者
Gordon, A [1 ]
VoipioPulkki, LM [1 ]
机构
[1] TURKU UNIV,CENT HOSP,MED INTENS CARE & CCU,TURKU,FINLAND
关键词
congestive heart failure; drug therapy; exercise; skeletal muscle;
D O I
10.3109/07853899708999356
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure syndrome is initiated as the body's metabolic needs temporarily exceed the pumping capacity of the heart. In most cases, this phenomenon tends to occur during physical exercise. Although not always subjectively recognized, limited exercise capacity remains the clinical hallmark of congestive heart failure, It can be measured objectively as reduced skeletal muscle performance and maximal whole-body oxygen uptake, which are not necessarily explained by central haemodynamic abnormalities, In fact, the initial cardiac condition sets forth a series of peripheral adaptations that are potentially life-saving during acute decompensation but become disadvantageous and symptom-generating in stable heart failure. Inodilator drugs were theoretically ideal to revert the adverse haemodynamic crosstalk between the heart and periphery. However, these drugs failed to improve prognosis in congestive heart failure, whereas drugs that did so showed typically unimpressive haemodynamic effects. Exercise therapy has recently emerged as a safe and effective way to enhance physical performance and subjective well-being in congestive heart failure, A dual therapeutic approach is suggested, consisting of exercise training to improve the periphery and the use of cardioprotective drugs to limit cardiac cellular damage from neurohormonal activation.
引用
收藏
页码:327 / 331
页数:5
相关论文
共 50 条
  • [1] Heart failure: a model of cardiac and skeletal muscle energetic failure
    B. Mettauer
    J. Zoll
    A. Garnier
    R. Ventura-Clapier
    Pflügers Archiv, 2006, 452 : 653 - 666
  • [2] Heart failure: a model of cardiac and skeletal muscle energetic failure
    Mettauer, B.
    Zoll, J.
    Garnier, A.
    Ventura-Clapier, R.
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2006, 452 (06): : 653 - 666
  • [3] Abnormalities of Skeletal Muscle, Adipocyte Tissue, and Lipid Metabolism in Heart Failure: Practical Therapeutic Targets
    Takada, Shingo
    Sabe, Hisataka
    Kinugawa, Shintaro
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
  • [4] Heart failure model for evaluation of skeletal muscle cardiac assist
    Orton, EC
    Monnet, E
    Boon, J
    CARDIAC BIOASSIST, 1997, 11 : 177 - 191
  • [5] Mitochondria as Therapeutic Targets in Heart Failure
    Julia Schwemmlein
    Christoph Maack
    Edoardo Bertero
    Current Heart Failure Reports, 2022, 19 : 27 - 37
  • [6] Emerging Therapeutic Targets for Heart Failure
    Maneesha Sharma
    Lokesh Kumar Bhatt
    Current Cardiology Reports, 2022, 24 : 1737 - 1754
  • [7] Kinases as therapeutic targets for heart failure
    Vlahos, CJ
    McDowell, SA
    Clerk, A
    NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (02) : 99 - 113
  • [8] Emerging Therapeutic Targets for Heart Failure
    Sharma, Maneesha
    Bhatt, Lokesh Kumar
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (11) : 1737 - 1754
  • [9] Kinases as therapeutic targets for heart failure
    Chris J. Vlahos
    Susan A. McDowell
    Angela Clerk
    Nature Reviews Drug Discovery, 2003, 2 : 99 - 113
  • [10] Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
    Gergely, Tamas G.
    Drobni, Zsofia D.
    Kallikourdis, Marinos
    Zhu, Han
    Meijers, Wouter C.
    Neilan, Tomas G.
    Rassaf, Tienush
    Ferdinandy, Peter
    Varga, Zoltan V.
    NATURE REVIEWS CARDIOLOGY, 2024, 21 (06) : 430 - 431